Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

New antibody-drug conjugates also kill non-targeted neighboring tumor cells

How do you kill tumor cells that can't be targeted? Get their more susceptible neighbors to help.

22 Jun 2021

Study uncovers new mechanisms underlying lineage plasticity

Cancer cells have an uncanny ability to evolve and adapt to overcome the treatments used against them. While patient survival has been extended by modern drugs that block the production or action of male hormones that fuel prostate cancer -- androgen receptor inhibitors such as enzalutamide, apalutamide, darolutamide, and abiraterone -- eventually these drugs stop working.

21 Jun 2021

PET/CT images can be used to measure biomarker levels, predict lung cancer outcomes

Tests that analyze biomarkers are used during cancer management to guide treatment and provide information about patient prognosis.

17 Jun 2021

Study uncovers novel drug that effectively thwarts pancreatic tumors

Pancreatic cancer is an aggressive disease in which malignant cells form in the tissues of the pancreas, a long and flat gland located behind the stomach that helps with digestion and blood sugar regulation.

14 Jun 2021

New drug shows promise against lung cancer caused by genetic mutation

The new drug sotorasib reduces tumor size and shows promise in improving survival among patients with lung tumors caused by a specific DNA mutation, according to results of a global phase 2 clinical trial.

8 Jun 2021

New drug reduces tumor size in lung cancer patients who have a specific, disease-causing change

A new drug reduced tumor size in patients who have lung cancer with a specific, disease-causing change in the gene KRAS, a study found.

7 Jun 2021

Study: Lung squamous patients harboring druggable mutations have lower median overall survival

Oncotarget published "Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations" which reported that unlike lung adenocarcinoma patients, there is no FDA-approved targeted-therapy likely to benefit lung squamous cell carcinoma patients.

3 Jun 2021

SWOG researchers to present practice-changing research at virtual ASCO 2021

"SWOG always brings an impressive portfolio of work to the ASCO annual meeting," said SWOG Chair Charles D. Blanke, MD, "and this year I'm particularly excited about the research our investigators are presenting because it includes results that are likely to be practice-changing."

1 Jun 2021

FDA approves targeted therapy for tumors with KRAS mutations

Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy.

29 May 2021

FDA approves Rybrevant for treating subset of non-small cell lung cancer

Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

21 May 2021

New approach combines molecular and medical imaging data to diagnose cancer type

Despite our remarkable advances in medicine and healthcare, the cure to cancer continues to elude us. On the bright side, we have made considerable progress in detecting several cancers in earlier stages, allowing doctors to provide treatments that increase long-term survival.

11 May 2021

Study identifies novel combination therapy to help patients with advanced lung cancer

A new study by researchers at the UCLA Jonsson Comprehensive Cancer Center has identified a novel combination therapy to potentially help overcome resistance to immunotherapy in people diagnosed with advanced lung cancer.

5 May 2021

Preoperative sarcopenia and exercise intolerance predict outcomes following lung cancer surgery

Lung cancer is a major global cause of mortality, reportedly accounting for 1.7 million deaths each year. The most common form of lung cancer is non-small-cell lung cancer (NSCLC), and early-stage NSCLCs can often be surgically resected.

26 Apr 2021

Contralateral esophagus sparing technique can prevent complication in lung cancer patients

For many patients with localized lung cancer (non-small-cell lung carcinoma and small cell lung carcinoma), high-dose radiation with concurrent chemotherapy is a potential cure. Yet this treatment can cause severe, acute inflammation of the esophagus (esophagitis) in about one in five patients, requiring hospitalization and placement of a feeding tube.

23 Apr 2021

Anti-diabetic drug phenformin may prompt stronger cancer-fighting activities

The anti-diabetic drug phenformin may prompt stronger cancer-fighting activities than its sister compound metformin, a finding that could have major implications for current and future clinical trials investigating both agents for their anti-cancer potential, according to researchers at Massachusetts General Hospital (MGH).

15 Apr 2021

New genetic markers may lead to personalized treatments for lung cancer

Investigators at Wake Forest School of Medicine, part of Wake Forest Baptist Health, have identified a set of new genetic markers that could potentially lead to new personalized treatments for lung cancer.

15 Apr 2021

Aneuploidy testing can be key in determining optimal treatment for lung cancer patients

Patients with non-small cell lung cancer (NSCLC) whose cancer cells have low levels of aneuploidy - an abnormal number of chromosomes - tend to respond better to immune checkpoint inhibitor drugs than patients with higher levels, Dana-Farber Cancer Institute researchers will report at the virtual AACR Annual Meeting 2021.

12 Apr 2021

Phase 3 clinical trial tests new treatment for brain metastases from small-cell lung cancer

A new phase 3 randomized clinical trial overseen by CU Cancer Center member Chad Rusthoven, MD, and Vinai Gondi, MD, from Northwestern University, is testing whether a new treatment approach could result in improved outcomes for patients with small cell lung cancer (SCLC) that has spread to the brain.

8 Apr 2021

Researchers discover two new ways to treat small cell lung tumors

Using samples of small cell lung tumors, a research team led by biologist Dr Silvia von Karstedt has discovered two new ways to induce tumor cell death. One of two subsets of tumor cells can be targeted by activating ferroptosis: iron-dependent cell death caused by oxidative stress

7 Apr 2021

High expression of cell death genes may increase risk of early death from lung cancer

Patients with a high number of genes most associated with pathways that lead to cell death in lung cancer are at increased risk of dying early from their disease, researchers report.

5 Apr 2021